Steven C. Quay - 20 Jan 2026 Form 4/A - Amendment Insider Report for ATOSSA THERAPEUTICS, INC. (ATOS)

Reporting relationship: President & CEO, Director
Issuer ticker: ATOS
Reported as of: 20 Jan 2026
Net transaction value: +$572,850
SEC form: 4/A - Amendment
Accepted by SEC: 30 Jan 2026, 08:30:03 UTC
Original report date: 22 Jan 2026
Prior SEC filing: 22 May 2025
Next SEC filing: 31 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Steven C. Quay

Key filing fact

Steven C. Quay filed Form 4/A - Amendment for ATOSSA THERAPEUTICS, INC. (ATOS) on 30 Jan 2026.

Key facts

This page summarizes Steven C. Quay's Form 4/A - Amendment filing for ATOSSA THERAPEUTICS, INC. (ATOS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 30 Jan 2026, 08:30.

Change

Previous filing in this sequence was filed on 22 May 2025.
Current net transaction value: +$572,850.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001008227 Primary reporting owner

QUAY STEVEN C

Relationship: President & CEO, Director
Address: C/O ATOSSA THERAPEUTICS, INC.,, 1448 NW MARKET STREET, SUITE 500, SEATTLE
Signature: /s/ Steven C. Quay
Signature date: 30 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATOS transaction

Common Stock

Award

Transaction value: $0
Shares: +331,674
Change %: +2386%
Price: $0.000000
Shares after: 345,572
Date: 20 Jan 2026
Ownership: Direct
Footnotes: F1, F2

ATOS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 22,254
Date: 20 Jan 2026
Ownership: By Ensisheim Partners, LLC
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATOS transaction Derivative

Stock Options (right to buy)

Award

Transaction value: $572,850
Shares: +950,000
Change %
Price: $0.6030
Shares after: 950,000
Date: 20 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 950,000
Exercise price: $0.6030
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents the acquisition of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest one year from the Transaction Date.

Footnote F2

The original Form 4, filed on January 22, 2026, is being amended by this Form 4 amendment solely to correct an administrative error regarding the number of RSUs acquired.

Footnote F3

Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Shu-Chih Chen. The Reporting Person and Dr. Chen share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Footnote F4

The options shall vest on a quarterly basis over 24 months following January 20, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on January 20, 2026, with an exercise price of $0.603, representing the closing stock price on January 20, 2026.